Artículos por temáticas

The role of microRNA-485 in neurodegenerative diseases

Ryu IS, Kim DH, Cho HJ, Ryu JH.

Rev Neurosci. 2022 Jul 7;34(1):49-62. doi: 10.1515/revneuro-2022-0039. Print 2023 Jan 27.

Glibenclamide as a neuroprotective antidementia drug

Zubov A, Muruzheva Z, Tikhomirova M, Karpenko M.

Arch Physiol Biochem. 2022 Dec;128(6):1693-1696. doi: 10.1080/13813455.2020.1789170. Epub 2020 Jul 11.

Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease

Abd-Elrahman KS, Ferguson SSG.

Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:235-254. doi: 10.1146/annurev-pharmtox-021821-091747. Epub 2021 Sep 13.

The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer's disease

Verma A, Kumar Waiker D, Bhardwaj B, Saraf P, Shrivastava SK.

Bioorg Chem. 2022 Feb;119:105562. doi: 10.1016/j.bioorg.2021.105562. Epub 2021 Dec 16.

Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders

Hölscher C.

Br J Pharmacol. 2022 Feb;179(4):695-714. doi: 10.1111/bph.15508. Epub 2021 May 29.

Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer's Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside

Walia V, Kaushik D, Mittal V, Kumar K, Verma R, Parashar J, Akter R, Rahman MH, Bhatia S, Al-Harrasi A, Karthika C, Bhattacharya T, Chopra H, Ashraf GM.

Mol Neurobiol. 2022 Jan;59(1):657-680. doi: 10.1007/s12035-021-02617-1. Epub 2021 Nov 9.

Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects

Tumati S, Herrmann N, Marotta G, Li A, Lanctôt KL.

Neurochem Int. 2022 Jan;152:105250. doi: 10.1016/j.neuint.2021.105250. Epub 2021 Dec 2.

[Sleep disorders in patients with a neurocognitive disorder]

Moderie C, Carrier J, Dang-Vu TT.

Encephale. 2022 Jun;48(3):325-334. doi: 10.1016/j.encep.2021.08.014. Epub 2021 Dec 14.

Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease

Takata K, Kimura H, Yanagisawa D, Harada K, Nishimura K, Kitamura Y, Shimohama S, Tooyama I.

Molecules. 2022 Apr 27;27(9):2780. doi: 10.3390/molecules27092780.

Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research

Yang H, Zeng F, Luo Y, Zheng C, Ran C, Yang J.

Molecules. 2022 Jun 17;27(12):3879. doi: 10.3390/molecules27123879.

A clinicopathological study of selected cognitive impairment cases in Lothian, Scotland: enhanced CJD surveillance in the 65 + population group

Kanguru L, Logan G, Waddel B, Smith C, Molesworth A, Knight R.

BMC Geriatr. 2022 Jul 20;22(1):603. doi: 10.1186/s12877-022-03280-4.

Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?

Martínez-Cué C, Bartesaghi R.

Nutrients. 2022 Jul 13;14(14):2880. doi: 10.3390/nu14142880.

Interleukin-17A in Alzheimer's Disease: Recent Advances and Controversies

Yan XZ, Lai L, Ao Q, Tian XH, Zhang YH.

Curr Neuropharmacol. 2022;20(2):372-383. doi: 10.2174/1570159X19666210823110004.

The multimodal action of genistein in Alzheimer's and other age-related diseases

Mas-Bargues C, Borrás C, Viña J.

Free Radic Biol Med. 2022 Apr;183:127-137. doi: 10.1016/j.freeradbiomed.2022.03.021. Epub 2022 Mar 26.

Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges

Han J, Chitu V, Stanley ER, Wszolek ZK, Karrenbauer VD, Harris RA.

Cell Mol Life Sci. 2022 Apr 2;79(4):219. doi: 10.1007/s00018-022-04225-1.